Korea United selected in Forbes Asia's "Best Under A Billion" list

Published: 2010-09-08 06:57:00

Updated: 2010-09-08 06:57:00

Korea United Pharmaceutical has continued to members of Forbes Asia's "Best Under A Billion" list for the second consecutive year, even as 151 new companies have made their maiden appearance on the list this year.

According to Fobes, Korea United Pharmaceutical's core offerings include anticancer drugs; antibiotics for various infections; circulatory drugs; vitamins; antifebrile and anodynes...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.